Synthetic silvestrol analogues as potent and selective protein synthesis inhibitors

Journal of Medicinal Chemistry

Volumn 55, Issue 20, 2012, Pages 8859-8878

  Liu, Tao ^a   Nair, Somarajan J ^a   Lescarbeau, André ^a   Belani, Jitendra ^a,b   Peluso, Stéphane ^a   Conley, James ^a   Tillotson, Bonnie ^a   OHearn, Patrick ^a   Smith, Sherri ^a   Slocum, Kelly ^a,c   West, Kip ^a   Helble, Joseph ^a   Douglas, Mark ^a   Bahadoor, Adilah ^a   Ali, Janid ^a   McGovern, Karen ^a   Fritz, Christian ^a   Palombella, Vito J ^a   Wylie, Andrew ^a,c   Castro, Alfredo C ^a   Tremblay, Martin R ^a   more..

^a Infinity Pharmaceuticals Inc   (United States)

^b Jefferson School of Pharmacy   (United States)

^c NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; PROTEIN SYNTHESIS INHIBITOR; SILVESTROL ANALOGUE; UNCLASSIFIED DRUG;

5' UNTRANSLATED REGION; ARTICLE; CONTROLLED STUDY; DRUG CYTOTOXICITY; MOUSE; NONHUMAN; PROTEIN SYNTHESIS INHIBITION; STRUCTURE ACTIVITY RELATION; TRANSLATION INITIATION;

5' UNTRANSLATED REGIONS; ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; DRUG SCREENING ASSAYS, ANTITUMOR; GENES, REPORTER; HUMANS; LUCIFERASES; MICE; MICROSOMES, LIVER; PROTEIN SYNTHESIS INHIBITORS; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TRITERPENES;

EID: 84867760869     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm3011542     Document Type: Article

References (49)

1. Silvera, D.; Formenti, S. C.; Schneider, R. J. Translational control in cancer Nat. Rev. Cancer 2010, 10, 254-266
2. Blagden, S. P.; Willis, A. E. The biological and therapeutic relevance of mRNA translation in cancer Nat. Rev. Clin. Oncol. 2011, 8, 280-291
3. Holland, E. C.; Sonenberg, N.; Pandolfi, P. P.; Thomas, G. Signaling control of mRNA translation in cancer pathogenesis Oncogene 2004, 23, 3138-3144
4. Hsieh, A. G.; Ruggero, D. Targeting eukaryotic translation initiation factor 4E (eIF4E) in cancer Clin. Cancer Res. 2010, 16, 4914-4920
5. Graff, J. R.; Konicek, B. W.; Carter, J. H.; Marcusson, E. G. Targeting the eurkaryotic translation initiation factor 4E for cancer therapy Cancer Res. 2008, 68, 631-634
6. DeBenedetti, A.; Graff, J. R. eIF-4E expression and its role in malignancies and metastases Oncogene 2004, 23, 3189-3199
7. Lazaris-Karatzas, A.; Montine, K. S.; Sonenberg, N. Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5 cap Nature 1990, 345, 544-547
8. She, Q.-B.; Halilovic, E.; Ye, Q.; Zhen, W.; Shirasawa, S.; Sasazuki, T.; Solit, D. B.; Rosen, N. 4E-BP1 is a key effector of the oncogenic activation of the AKT and ERK signaling pathways that integrates their function in tumors Cancer Cell 2010, 18, 39-51
9. Hsieh, A. G.; Costa, M.; Zollo, O.; Davis, C.; Feldman, M. E.; Testa, J. R.; Meyuhas, O.; Shokat, K. M.; Ruggero, D. Genetic dissection of the oncogenic mTOR pathway reveals druggable addiction to translational control via 4EBP-eIF4E Cancer Cell 2010, 17, 249-261
10. Yang, H.-S.; Jansen, A. P.; Komar, A. A.; Zheng, X.; Merrick, W. C.; Costes, S.; Lockett, S. J.; Sonenberg, N.; Colburn, N. H. The transformation suppressor Pdcd4 is a novel eukaryotic translation initiation factor 4A binding protein that inhibits translation Mol. Cell. Biol. 2003, 23, 26-37
11. Jansen, A. P.; Camalier, C. E.; Stark, C.; Colburn, N. H. Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity Mol. Cancer Ther. 2004, 3, 103-110
12. Svitkin, Y. V.; Pause, A.; Haghighat, A.; Pyronnet, S.; Witherell, G.; Belsham, G. J.; Sonenberg, N. The requirement for eukaryotic initiation factor 4A (eIF4A) in translation is in direct proportion to the degree of mRNA 59 secondary structure RNA 2001, 7, 382-394
13. Kozak, M. An analysis of vertebrate mRNA sequences: intimations of translational control J. Cell Biol. 1991, 115, 887-903
14. Aktas, B. H.; Halperin, J. A.; Wagner, G.; Chorev, M. Inhibition of translation initiation as a novel paradigm for cancer therapy Annu. Rep. Med. Chem. 2011, 46, 189-210
15. Lindqvist, L.; Pelletier, J. Inhibitors of translation initiation as cancer therapeutics Future Med. Chem. 2009, 1, 1709-1722
16. Bordeleau, M.-E.; Robert, F.; Gerard, B.; Lindqvist, L.; Chen, S. M. H.; Wendel, H.-G.; Brem, B.; Greger, H.; Lowe, S. W.; Porco, J. A., Jr.; Pelletier, J. Therapeutic suppression of translation initiation modulates chemosensitivity in a mouse lymphoma model J. Clin. Invest. 2008, 118, 1-11
17. Cencic, R.; Carrier, M.; Galicia-Vázquez, G.; Bordeleau, M.-E.; Sukarieh, R.; Bourdeau, A.; Brem, B.; Teodoro, J. G.; Greger, H.; Tremblay, M. L.; Porco, J. A., Jr.; Pelletier, J. Antitumor activity and mechanism of action of the cyclopenta[ b ]benzofuran, silvestrol PLoS One 2009, 4, e5223
18. Hwang, B. Y.; Su, B.-N.; Chai, H.; Mi, Q.; Leonardus, B. S.; Kardono; Afriastini, J. J.; Riswan, S.; Santarsiero, B. D.; Mesecar, A. D.; Wild, R.; Fairchild, C. R.; Vite, G. D.; Rose, W. C.; Farnsworth, N. R.; Cordell, G. A.; Pezzuto, J. M.; Swanson, S. M.; Kinghorn, A. D. Silvestrol and episilvestrol, potential anticancer rocaglate derivatives from Aglaia silvestris J. Org. Chem. 2004, 69, 3350-3358
19. Meurer-Grimes, B. M.; Yu, J.; Vairo, G. L. Therapeutic Compounds and Methods. US 6,710,075 B2, 2004.
20. Lucas, D. M.; Edwards, R. B.; Lozanski, G.; West, D. A.; Shin, J. D.; Vargo, M. A.; Davis, M. E.; Rozewski, D. M.; Su, A. J. J. B.-N.; Goettl, V. M.; Heerema, N. A.; Lin, T. S.; Lehman, A.; Zhang, X.; Jarjoura, D.; Newman, D. J.; Byrd, J. C.; Kinghorn, D.; Grever, M. R. The novel plant-derived agent silvestrol has B-cell selective activity in chronic lymphocytic leukemia and acute lymphoblastic leukemia in vitro and in vivo Blood 2009, 113, 4656-4666
21. Alinari, L.; Prince, C. J.; Edwards, R. B.; Towns, W.; Mani, R.; Lehman, A.; Zhang, X.; Jarjoura, D.; Pan, L.; Kinghorn, A. D.; Grever, M. R.; Baiocchi, R. A.; Lucas, D. M. Dual targeting of the cyclin/Rb/E2F and mitochondrial pathways in mantle cell lymphoma with the translation inhibitor silvestrol Clin. Cancer Res. 2012, 18, 4600-4611
22. Ribeiro, N.; Thuaud, F.; Nebigil, C.; Désaubry, L. Recent advances in the biology and chemistry of flavaglines Bioorg. Med. Chem. 2012, 20, 1857-1864
23. Kim, S.; Salimb, A. A.; Swanson, S. M.; Kinghorn, A. D. Potential of cyclopenta[ b ]benzofurans from Aglaia species in cancer chemotherapy Anti-Cancer Agents Med. Chem. 2006, 6, 318-345
24. Proksch, P.; Edrada, R.; Ebel, R.; Bohnenstengel, F. I.; Nugroho, B. W. Chemistry and biological activity of rocaglamide derivatives and related compounds in Aglaia species (meliaceae) Curr. Org. Chem. 2001, 5, 923-938
25. Lee, S. K.; Cui, B.; Mehta, R. R.; Kinghorn, A. D.; Pezzuto, J. M. Cytostatic mechanism and antitumor potential of novel 1 H -cyclopenta[ b ]benzofuran lignans isolated from Aglaia elliptica Chem.-Biol. Interact. 1998, 115, 215-228
26. Bohnenstengel, F. I.; Steube, K. G.; Meyer, C.; Quentmeier, H.; Nugroho, B. W.; Proksch, P. 1H-Cyclopenta[ b ]benzofuran lignans from Aglaia species inhibit cell proliferation and alter cell cycle distribution in human monocytic leukemia cell lines Z. Naturforsch., C: J. Biosci. 1999, 54, 1075-1083
27. Gerard, B.; Cencic, R.; Pelletier, J.; Porco, J. A., Jr. Enantioselective synthesis of the complex rocaglate (-)-silvestrol Angew. Chem., Int. Ed. 2007, 46, 7831-7834
28. Adams, T. E.; El Sous, M.; Hawkins, B. C.; Hirner, S.; Holloway, G.; Khoo, M. L.; Owen, D. J.; Savage, G. P.; Scammells, P. J.; Rizzacasa, M. A. Total synthesis of the potent anticancer Aglaia metabolites (-)-silvestrol and (-)-episilvestrol and the active analogue (-)-4′-desmethoxyepisilvestrol J. Am. Chem. Soc. 2009, 131, 1607-1616
29. El Sous, M.; Khoo, M. L.; Holloway, G.; Owen, D.; Scammells, P. J.; Rizzacasa, M. A. Total synthesis of (-)-episilvestrol and (-)-silvestrol Angew. Chem., Int. Ed. 2007, 46, 7835-7838
30. Chambers, J. M.; Huang, D. C. S.; Lindqvist, L. M.; Savage, G. P.; White, J. M.; Rizzacasa, M. A. Total synthesis of 2,5-diepisilvestrol and its C1 epimer: key structure activity relationships at C1 and C2 J. Nat. Prod. 2012, 75, 1500-1504
31. Pan, L.; Kardono, L. B. S.; Riswan, S.; Chai, H.; Blanco, E. J. C. d.; Pannell, C. M.; Soejarto, D. D.; McCloud, T. G.; Newman, D. J.; Kinghorn, A. D. Isolation and characterization of minor analogues of silvestrol and other constituents from a large-scale re-collection of Aglaia foveolata J. Nat. Prod. 2010, 73, 1873-1878
32. Kim, S.; Hwang, B. Y.; Su, B.-N.; Chai, H.; Mi, Q.; Kinghorn, A. D.; Wild, R.; Swanson, S. M. Silvestrol, a potential anticancer rocaglate derivative from Aglaia foveolata, induces apoptosis in LNCaP cells through the mitochondrial/apoptosome pathway without activation of executioner caspase-3 or -7 Anticancer Res. 2007, 27, 2175-2183
33. Mi, Q.; Kim, S.; Hwang, B. Y.; Su, B.-N.; Chai, H.; Arbieva, Z. H.; Kinghorn, A. D.; Swanson, S. M. Silvestrol regulates G2/M checkpoint genes independent of p53 activity Anticancer Res. 2006, 26, 3349-3356
34. El Sous, M.; Rizzacasa, M. A. Biomimetic synthesis of the novel 1,4-dioxanyloxy fragment of silvestrol and episilvestrol Tetrahedron Lett. 2005, 46, 293-295
35. Owen, D. J.; Rizzacasa, M. A.; El Sous, M.; Spiniello, M.; Scammells, P. J.; Holloway, G. Preparation of Cyclic Compounds Bearing a Dioxanyl Moiety. WO2006007634, 2006.
36. Thuaud, F.; Ribeiro, N.; Gaiddon, C.; Cresteil, T.; Desaubry, L. Novel flavaglines displaying improved cytotoxicity J. Med. Chem. 2011, 54, 411-415
37. Rodrigo, C. M.; Cencic, R.; Roche, S. P.; Pelletier, J.; Porco, J. A., Jr. Synthesis of rocaglamide hydroxamates and related compounds as eukaryotic translation inhibitors: synthetic and biological studies J. Med. Chem. 2012, 55, 558-562
38. Roche, S. P.; Cencic, R.; Pelletier, J.; Porco, J. A., Jr. Biomimetic photocycloaddition of 3-hydroxyflavones: synthesis and evaluation of rocaglate derivatives as inhibitors of eukaryotic translation Angew. Chem., Int. Ed. 2010, 49, 6533-6538
39. Rubottom, G. M.; Vazquez, M. A.; Pelegrina, D. R. Peracid oxidation of trimethylsilyl enol ethers. Facile α-hydroxylation procedure Tetrahedron Lett. 1974, 4319-4322
40. Fougerousse, A.; Gonzalez, E.; Brouillard, R. A convenient method for synthesizing 2-aryl-3-hydroxy-4-oxo-4 H -1-benzopyrans or flavonols J. Org. Chem. 2000, 65, 583-586
41. Bennett, C. J.; Caldwell, S. T.; McPhail, D. B.; Morrice, P. C.; Duthie, G. G.; Hartley, R. C. Potential therapeutic antioxidants that combine the radical scavenging ability of myricetin and the lipophilic chain of vitamin E to effectively inhibit microsomal lipid peroxidation Bioorg. Med. Chem. 2004, 12, 2079-2098
42. Sugimura, T.; Hagiya, Z. Di-2-methoxyethyl azodicarboxylate (DMEAD): an inexpensive and separation-friendly alternative reagent for the Mitsunobu reaction Chem. Lett. 2007, 36, 566-567
43. Pericas, M. A.; Riera, A.; Giralt, E. Conformational analysis of trans -2,3-diaryloxy-1,4-dioxanes. A tool for discrimating between steric and electronic effects in the position of the conformational equilibria of substituted dioxanes Tetrahedron 1985, 41, 3785-3789
44. Thuaud, F.; Bernard, Y.; Turkeri, G.; Dirr, R.; Aubert, G.; Cresteil, T.; Baguet, A.; Tomasetto, C.; Svitkin, Y.; Sonenberg, N.; Nebigil, C. G.; Desaubry, L. Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12 J. Med. Chem. 2009, 52, 5176-5187
45. Saradhi, U. V. R. V.; Gupta, S. V.; Chiu, M.; Wang, J.; Ling, Y.; Liu, Z.; Newman, D. J.; Covey, J. M.; Kinghorn, A. D.; Marcucci, G.; Lucas, D. M.; Grever, M. R.; Phelps, M. A.; Chan, K. K. Characterization of silvestrol pharmacokinetics in mice using liquid chromatography-tandem mass spectrometry AAPS J. 2011, 13, 347-356
46. Gupta, S. V.; Sass, E. J.; Davis, M. E.; Edwards, R. B.; Lozanski, G.; Heerema, N. A.; Lehman, A.; Zhang, X.; Jarjoura, D.; Byrd, J. C.; Pan, L.; Chan, K. K.; Kinghorn, A. D.; Phelps, M. A.; Grever, M. R.; Lucas, D. M. Resistance to the translation initiation inhibitor silvestrol is mediated by ABCB1/P-glycoprotein overexpression in acute lymphoblastic leukemia cells AAPS J. 2011, 13, 357-364
47. Hofacker, I. L. Vienna RNA secondary structure server Nucleic Acids Res. 2003, 31, 3429-3431
48. Cruz-Migoni, A.; Hautbergue, G. M.; Artymiuk, P. J.; Baker, P. J.; Bokori-Brown, M.; Chang, C.-T.; Dickman, M. J.; Essex-Lopresti, A.; Harding, S. V.; Mahadi, N. M.; Marshall, L. E.; Mobbs, G. W.; Mohamed, R.; Nathan, S.; Ngugi, S. A.; Ong, C.; Ooi, W. F.; Partridge, L. J.; Phillips, H. L.; Raih, M. F.; Ruzheinikov, S.; Sarkar-Tyson, M.; Sedelnikova, S. E.; Smither, S. J.; Tan, P.; Titball, R. W.; Wilson, S. A.; Rice1, D. W. A Burkholderia pseudomallei toxin inhibits helicase activity of translation factor eIF4A Science 2011, 334, 821-824
49. Tsumuraya, T.; Ishikawa, C.; Machijima, Y.; Nakachi, S.; Senba, M.; Tanaka, J.; Mori, N. Effects of hippuristanol, an inhibitor of eIF4A, on adult T-cell leukemia Biochem. Pharmacol. 2011, 81, 713-722